400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
2023-07-13
抗癌治疗药物开发商
医药研发/制造
化学&生物药
2023-05-16
口服小分子候选药物研发商
医药研发/制造
化学&生物药
New Enterprise Associate;
New Enterprise Associate;
Stonepine Capital Management;
Stonepine Capital Management;
Kingdon Capital;
Acorn Bioventures;
奥博资本;
Adage Capital Management;
Bain Capital
2022-11-03
细胞和基因疗法开发商
医药研发/制造
化学&生物药
Nantahala Capital Management;
Nantahala Capital Management;
EcoR1 Capital;
EcoR1 Capital;
Deerfield;
Armistice Capital;
Adage Capital Management
2021-12-08
医疗网络平台提供商
综合服务
社群服务
Park West Asset Management;
Park West Asset Management;
HBM Healthcare;
HBM Healthcare;
鱼鹰资管;
Adage Capital Management;
Avidity Partners;
Suvretta Capital Management
2021-10-27
靶向TRK疗法研发商
医药研发/制造
化学&生物药
Oracle Investment Management;
Oracle Investment Management;
Averill Master Fund;
Averill Master Fund;
J.W. Childs Associates;
Adage Capital Management
2021-10-19
基因疗法研发商
医药研发/制造
化学&生物药
Digitalis Ventures;
Digitalis Ventures;
奥博资本;
奥博资本;
Adage Capital Management;
Frazier Management;
Greenspring Associates;
RiverVest;
Correlation Ventures
2021-10-12
高血压靶向治疗药物研发商
医药研发/制造
Omega Funds;
Omega Funds;
泛大西洋投资;
泛大西洋投资;
Perceptive Advisors;
RTW Investments;
Sofinnova Partners;
Sixty Degree Capital;
VenBio Partners;
Adage Capital Management;
CinRx;
5AM Ventures;
Rock Springs Capital;
BVF Partners
2021-08-16
迷幻药物研发商
医药研发/制造
化学&生物药
Palo Santo Venture Fund;
Palo Santo Venture Fund;
Integrated;
Integrated;
Adage Capital Management
2021-08-05
神经肌肉疾病治疗药物研发商
医药研发/制造
化学&生物药
Samsara BioCapital;
Samsara BioCapital;
CureDuchenne Ventures;
CureDuchenne Ventures;
Oxford Sciences Innovation;
Deerfield;
RA Capital;
Laurion Capital Management;
Adage Capital Management;
Tudor Investment Corporation;
Viking Global Investors
2021-05-23
临床阶段免疫肿瘤学研究商
医药研发/制造
化学&生物药
Point 72;
Point 72;
3×5 Partners;
3×5 Partners;
Eventide Asset Management;
Roche Venture Fund;
Avego Healthcare Capital;
Adage Capital Management;
Cowen Healthcare Investments;
Lightchain;
RiverVest;
Broadfin Capital;
GlobeNewswire2026-03-10
PRNewswire2026-03-10
PRNewswire2026-03-10
GlobeNewswire2026-03-10
PRNewswire2026-03-10
GlobeNewswire2026-03-10
PRNewswire2026-03-10
GlobeNewswire2026-03-10
PRNewswire2026-03-10
PRNewswire2026-03-10